ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Immune-Related Adverse Events Predict the Efficacy of Immune Checkpoint Inhibitors in Lung Cancer Patients: A Meta-Analysis

Wang, Donghui; Chen, Cen; Gu, Yanli; Lu, Wanjun; Zhan, Ping; Liu, Hongbing; Lv, Tangfeng; Song, Yong*; Zhang, Fang*南方医科大学; 南京大学; 1; y
Frontiers in Oncology2021-3-1DOI: 10.3389/fonc.2021.631949
34被引14阅读
引用收藏
分享

摘要

Background @@@ Immune-related adverse events (irAEs) have been reported to be associated with the efficacy of immunotherapy. Herein, we conducted a meta-analysis to demonstrate that irAEs could predict the efficacy of immune checkpoint inhibitors (ICIs) in lung cancer patients. @@@ Methods @@@ Literature on the correlation between irAEs and the efficacy of immunotherapy in lung cancer patients were searched to collect the data on objective response rate (ORR), overall survival (OS), or progression-free survival (PFS) of the patients. These data were incorporated into the meta-analysis. @@@ Results @@@ A total of 34 records encompassing 8,115 patients were examined in this study. The irAEs occurrence was significantly associated with higher ORR {risk ratio (RR): 2.43, 95% confidence interval (CI) [2.06-2.88], p < 0.00001} and improved OS {hazard ratio (HR): 0.51, 95% CI [0.43-0.61], p < 0.00001}, and PFS (HR: 0.50, 95% CI [0.44-0.57], p < 0.00001) in lung cancer patients undergoing ICIs. Subgroup analysis revealed that OS was significantly longer in patients who developed dermatological (OS: HR: 0.53, 95%CI [0.42-0.65], p < 0.00001), endocrine (OS: HR: 0.55, 95%CI [0.45-0.67], p < 0.00001), and gastrointestinal irAEs (OS: HR: 0.58, 95%CI [0.42-0.80], p = 0.0009) than in those who did not. However, hepatobiliary, pulmonary, and high-grade (>= 3) irAEs were not correlated with increased OS and PFS. @@@ Conclusion @@@ The occurrence of irAEs in lung cancer patients, particularly dermatological, endocrine, and gastrointestinal irAEs, is a predictor of enhanced ICIs efficacy.

学科与关键词

关键词
immune-related adverse events (irAEs)efficacyimmune checkpoint inhibitors (ICIS)lung cancermeta-analysis
相关
加载中…
  • Immune checkpoint inhibitor-related adverse events in lung cancer: Real-world incidence and management practices of 1905 patients in China
    Shi, Yuequan; Fang, Jian; Zhou, Chengzhi; Liu, Anwen; Wang, Yan; Meng, Qingwei; Ding, Cuimin; Ai, Bin; Gu, Yangchun; Yao, Yu; Sun, Hong; Guo, Hui; Zhang, Cuiying; Song, Xia; Li, Junling; Xu, Bei; Han, Zhiqiang; Song, Meijun; Tang, Tingyu; Chen, Peifeng; Lu, Hongmin; Shui, Yongjie; Lou, Guangyuan; Zhang, Dongming; Liu, Jia; Liu, Xiaoyan; Liu, Xiangning; Gao, Xiaoxing; Zhou, Qing; Chen, Minjiang; Zhao, Jing; Zhong, Wei; Xu, Yan; Wang, Mengzhao*Thoracic Cancer, 2022, 13(3): 412-422.被引 15
  • The Predictive Model Construction for Immune-Related Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immunotherapy
    Gao, Weitong; Liu, Qianqian; Zhou, Yang; Yang, Min; Yu, Yan*TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2023, 22: 15330338231206705.
  • Understanding the functional inflammatory factors involved in therapeutic response to immune checkpoint inhibitors for pan-cancer
    Wu, Yanmeizhi; Yu, Shan*; Qiao, Hong*Frontiers in Pharmacology, 2022, 13: 990445.被引 3
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Oncology
发表日期
2021-03-01
卷期
第 11 卷
页码
631949
DOI
10.3389/fonc.2021.631949
期刊收录
NSL
期刊等级
3区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [81970034, 81570078]

作者

  • W

    Wang, Donghui (第一作者)

    nanjing med univ

  • C

    Chen, Cen

    1 · southern med univ

查看全部 9 位作者收起作者
  • G

    Gu, Yanli

    nanjing med univ

  • L

    Lu, Wanjun

    nanjing univ

  • Z

    Zhan, Ping

    nanjing univ

  • L

    Liu, Hongbing

    nanjing univ

  • L

    Lv, Tangfeng

    nanjing univ

  • S

    Song, Yong (通讯)

    nanjing univ

  • Z

    Zhang, Fang (通讯)

    nanjing med univ · nanjing univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417